Prevention of cardiac transplant rejection

Prevention of cardiac transplant rejection refers to the prophylactic inhibition of the recipient immune system to avert host-versus-graft immune responses following heart transplantation Pathophysiologically, unmitigated rejection leads to myocardial lymphocytic infiltration, microvascular endothelial injury, progressive myocardial necrosis, and eventual graft dysfunction or failure

Prevention of cardiac transplant rejection refers to the prophylactic inhibition of the recipient immune system to avert host-versus-graft immune responses following heart transplantation

This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy Prophylaxis preserves donor cardiac function by suppressing alloimmune recognition and effector pathways throughout induction and long-term maintenance phases

This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy Pathophysiologically, unmitigated rejection leads to myocardial lymphocytic infiltration, microvascular endothelial injury, progressive myocardial necrosis, and eventual graft...

This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy

This clinical indication targets allograft recipients at risk of acute or chronic immune-mediated graft injury, which can manifest as T-cell–mediated acute cellular rejection, antibody-mediated rejection involving donor-specific antibodies against donor human leukocyte antigens, or late-stage cardiac allograft vasculopathy

Prophylaxis preserves donor cardiac function by suppressing alloimmune recognition and effector pathways throughout induction and long-term maintenance phases